File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma

TitleAddition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma
Authors
Issue Date2008
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
Journal Of Clinical Oncology, 2008, v. 26 n. 28, p. 4587-4594 How to Cite?
AbstractPurpose: Diffuse large B-cell lymphoma (DLBCL) includes at least two prognostically important subtypes (ie, germinal center B-cell-like [GCB] and activated B-cell-like [ABC] DLBCL), which initially were characterized by gene expression profiling and subsequently were confirmed by immunostaining. However, with the addition of rituximab to standard chemotherapy, the prognostic significance of this subclassification of DLBCL is unclear. Patients and Methods: We studied 243 patient cases of de novo DLBCL, which included 131 patient cases treated with rituximab plus standard chemotherapy (rituximab group) and 112 patient cases treated with only standard chemotherapy (control group). The cases were assigned to GCB or non-GCB subgroups (the latter of which included both ABC DLBCL and unclassifiable DLBCL) on the basis of immunophenotype by using the Hans method. Clinical characteristics and survival outcomes of the two patient groups were compared. Results: The clinical characteristics of the patients in the rituximab and the control groups were similar. Compared with the control group, addition of rituximab improved the 3-year overall survival (OS; 42% v 77%; P < .001) of patients with DLBCL. Rituximab-treated patients in either the GCB or the non-GCB subgroups also had a significantly improved 3-year OS compared with their respective subgroups in the control group (P < .001). In the rituximab group, the GCB subgroup had a significantly better 3-year OS than the non-GCB subgroup (85% v 69%; P = .032). Multivariate analyses confirmed that rituximab treatment was predictive for survival in both the GCB and the non-GCB subgroups. Conclusion: In this retrospective study, we have shown that the subclassification of DLBCL on the basis of the cell of origin continues to have prognostic importance in the rituximab era. © 2008 by American Society of Clinical Oncology.
Persistent Identifierhttp://hdl.handle.net/10722/60562
ISSN
2015 Impact Factor: 20.982
2015 SCImago Journal Rankings: 9.204
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorFu, Ken_HK
dc.contributor.authorWeisenburger, DDen_HK
dc.contributor.authorChoi, WWLen_HK
dc.contributor.authorPerry, KDen_HK
dc.contributor.authorSmith, LMen_HK
dc.contributor.authorShi, Xen_HK
dc.contributor.authorHans, CPen_HK
dc.contributor.authorGreiner, TCen_HK
dc.contributor.authorBierman, PJen_HK
dc.contributor.authorBociek, RGen_HK
dc.contributor.authorArmitage, JOen_HK
dc.contributor.authorChan, WCen_HK
dc.contributor.authorVose, JMen_HK
dc.date.accessioned2010-05-31T04:13:43Z-
dc.date.available2010-05-31T04:13:43Z-
dc.date.issued2008en_HK
dc.identifier.citationJournal Of Clinical Oncology, 2008, v. 26 n. 28, p. 4587-4594en_HK
dc.identifier.issn0732-183Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/60562-
dc.description.abstractPurpose: Diffuse large B-cell lymphoma (DLBCL) includes at least two prognostically important subtypes (ie, germinal center B-cell-like [GCB] and activated B-cell-like [ABC] DLBCL), which initially were characterized by gene expression profiling and subsequently were confirmed by immunostaining. However, with the addition of rituximab to standard chemotherapy, the prognostic significance of this subclassification of DLBCL is unclear. Patients and Methods: We studied 243 patient cases of de novo DLBCL, which included 131 patient cases treated with rituximab plus standard chemotherapy (rituximab group) and 112 patient cases treated with only standard chemotherapy (control group). The cases were assigned to GCB or non-GCB subgroups (the latter of which included both ABC DLBCL and unclassifiable DLBCL) on the basis of immunophenotype by using the Hans method. Clinical characteristics and survival outcomes of the two patient groups were compared. Results: The clinical characteristics of the patients in the rituximab and the control groups were similar. Compared with the control group, addition of rituximab improved the 3-year overall survival (OS; 42% v 77%; P < .001) of patients with DLBCL. Rituximab-treated patients in either the GCB or the non-GCB subgroups also had a significantly improved 3-year OS compared with their respective subgroups in the control group (P < .001). In the rituximab group, the GCB subgroup had a significantly better 3-year OS than the non-GCB subgroup (85% v 69%; P = .032). Multivariate analyses confirmed that rituximab treatment was predictive for survival in both the GCB and the non-GCB subgroups. Conclusion: In this retrospective study, we have shown that the subclassification of DLBCL on the basis of the cell of origin continues to have prognostic importance in the rituximab era. © 2008 by American Society of Clinical Oncology.en_HK
dc.languageengen_HK
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/en_HK
dc.relation.ispartofJournal of Clinical Oncologyen_HK
dc.subject.meshAntibodies, Monoclonal - administration and dosage-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - administration and dosage - therapeutic use-
dc.subject.meshLymphoma, Large B-Cell, Diffuse - drug therapy - pathology-
dc.subject.meshProportional Hazards Models-
dc.subject.meshVincristine - administration and dosage-
dc.titleAddition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0732-183X&volume=26&issue=28&spage=4587&epage=4594&date=2008&atitle=Addition+of+rituximab+to+standard+chemotherapy+improves+the+survival+of+both+the+germinal+center+B-cell-like+and+non-germinal+center+B-cell-like+subtypes+of+diffuse+large+B-cell+lymphomaen_HK
dc.identifier.emailChoi, WWL:wlchoi@pathology.hku.hken_HK
dc.identifier.authorityChoi, WWL=rp00247en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1200/JCO.2007.15.9277en_HK
dc.identifier.pmid18662967-
dc.identifier.scopuseid_2-s2.0-53749093794en_HK
dc.identifier.hkuros160187en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-53749093794&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume26en_HK
dc.identifier.issue28en_HK
dc.identifier.spage4587en_HK
dc.identifier.epage4594en_HK
dc.identifier.eissn1527-7755-
dc.identifier.isiWOS:000259648300014-
dc.publisher.placeUnited Statesen_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats